Wall Street Transcript Interview with Dolev Rafaeli, the CEO & Dennis M. McGrath, the CFO, President and Director of PhotoMedex, Inc. (PHMD)

Wall Street Transcript

67 WALL STREET, New York - August 2, 2013 - The Wall Street Transcript has just published its Medical Devices Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Orthopedics and Cardiovascular Medical Devices - Medical Device Innovation and Consolidation Trends - Cardiac - Health Care - Affordable Care Act - Continued Pricing Pressure - Aging U.S. Population

Companies include: PhotoMedex, Inc. (PHMD) and many more.

In the following excerpt from the Medical Devices Report, the CEO & the CFO, President and Director of PhotoMedex, Inc. (PHMD) discuss company strategy and the outlook for this vital industry:

TWST: Could you give us a sampling of some of your proprietary products, where they are found and some of their applications?

Mr. McGrath: As Dolev said, the companies have combined to create what we consider a full product life cycle, from the genesis of an idea through the development stage, attracting the right scientific advisory board, monitoring these products in the physician community and ultimately miniaturizing them and selling directly to the consumer. We have leveraged the natural life cycle of these products by developing a world-class marketing platform that has simply cracked the code to draw consumers in, so you find our diversified product offerings along that entire spectrum.

In the physician community, our XTRAC brand name is the safest and most effective therapy for psoriasis. It's a laser device that emits UV light at specific wavelengths that clears psoriasis from the patient's body for extended periods of time. This fulfills a previously unmet need in the psoriasis patient's life, and it works very painlessly. We also go to market with a very unique business model for the physician and one that creates recurring revenue.

In addition, we sell skin care products to physicians who in turn retail them to their patients. These products have two proprietary ingredients: DNA repair enzymes, which reverse the effect of sun damage, and copper peptides. Copper has been studied for years for its wound-healing applications, and it's proven to increase the collagen and elasticity of the skin. Historically these products have been sold into the physician market. We've adapted that model to now include a consumer platform, selling directly to the consumer.

A perfect example of...

For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

View Comments (0)